GnomeDX Launches Personalized Medicine Services to Improve Patient Outcomes and Reduce Health Care Costs

Guía de Regalos

COLUMBUS, Ohio–(BUSINESS WIRE)–Gnome Diagnostics, LLC (GnomeDX), a CLIA-certified personalized medicine
company, announced the launch of its pharmacogenomic testing services –
healthcare’s newest forefront of personalized medicine for patients.

Adverse drug reactions are the 4th leading cause of death in the United
States ahead of stroke, Alzheimer’s disease, and diabetes, and are
estimated to account for $136 billion dollars in health care costs
annually. Today, the FDA includes pharmacogenetic information on 137
prescription labels, such as Warfarin and Plavix, detailing the
potential risks to taking a drug based on an individual’s genetics.

A simple cotton swab of the inner cheek can be the difference between a
patient’s best opportunity for drug efficacy or the unnecessary trial
and error of taking a drug that may lead to an adverse drug response.
GnomeDX’s test results are presented in a clear and concise report that
helps clinicians choose the right drug at the right dose for the right
person.

“For the first time, the cost of genomic testing is low enough to become
a routine medical test to help identify which drugs are best for
patients. Often times patients will either not respond to certain drugs
or may experience life threatening side effects many of which can often
be prevented by a simple test. In addition, utilizing these tests will
not only dramatically improve patient outcomes, but also will save an
enormous amount of money,” says founder Adel Mikhail, Ph.D.

Testing services are immediately available for clinicians to order, and
are often covered by Medicare and insurance. Tests range from cardiology
to mental health to pain management. For more information on how
pharmacogenetics can benefit patients, contact GnomeDX at gnomedx.com.

About Gnome Diagnostics: GnomeDX’s genetic tests help
physicians to prescribe the safest and most effective dose based on an
individual’s unique genetic profile. In addition, the GnomeDX panel
tests can screen for inherited cardiovascular disease risk, promoting
early detection and prevention. GnomeDX’s goal is to improve the
treatment outcomes for patients, minimize risk and side effects from
prescription drugs, and help reduce the overall cost of healthcare.

“Because medicine starts with me.”

Contacts

Gnome Diagnostics, LLC
Madison Bush, 614-431-6414
madison@gnomedx.com